• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC.

作者信息

Pérol Maurice

机构信息

Department of Medical Oncology, Léon Bérard Cancer Center, 69008 Lyon, France.

出版信息

Transl Lung Cancer Res. 2014 Dec;3(6):392-4. doi: 10.3978/j.issn.2218-6751.2014.09.06.

DOI:10.3978/j.issn.2218-6751.2014.09.06
PMID:25806330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4367676/
Abstract
摘要

相似文献

1
Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC.METLung研究的阴性结果：一个更好理解MET通路在晚期非小细胞肺癌中作用的机会。
Transl Lung Cancer Res. 2014 Dec;3(6):392-4. doi: 10.3978/j.issn.2218-6751.2014.09.06.
2
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.MetLung 试验的治疗原理研究设计：一项 Onartuzumab（MetMAb）联合厄洛替尼与厄洛替尼单药治疗标准化疗后 IIIB 或 IV 期 MET 阳性非小细胞肺癌患者的随机、双盲 III 期研究。
Clin Lung Cancer. 2012 Nov;13(6):500-4. doi: 10.1016/j.cllc.2012.05.009.
3
First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.一线使用奥那珠单抗联合厄洛替尼治疗MET阳性且EGFR突变阳性的非小细胞肺癌患者。
Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.
4
Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.奥希替尼联合或不联合 savolitinib 治疗初治 MET 外显子 14 跳跃突变、EGFR 突变型晚期非小细胞肺癌的 II 期、随机、开放标签、两队列多中心干预研究的设计和原理： FLOWERS 试验。
Clin Lung Cancer. 2023 Jan;24(1):82-88. doi: 10.1016/j.cllc.2022.09.009. Epub 2022 Sep 30.
5
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.METLung：奥沙利umab 联合厄洛替尼对比厄洛替尼治疗既往治疗的 IIIB 或 IV 期非小细胞肺癌的 III 期随机试验结果
J Clin Oncol. 2017 Feb;35(4):412-420. doi: 10.1200/JCO.2016.69.2160. Epub 2016 Dec 12.
6
Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring , , or Alterations.携带、或改变的晚期非鳞状非小细胞肺癌患者一线免疫治疗的真实世界治疗模式与结局
JTO Clin Res Rep. 2023 Aug 23;4(10):100568. doi: 10.1016/j.jtocrr.2023.100568. eCollection 2023 Oct.
7
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.PI3K 通路改变导致携 MET 外显子 14 跳跃突变的 NSCLC 对 MET 抑制剂产生耐药性。
J Thorac Oncol. 2020 May;15(5):741-751. doi: 10.1016/j.jtho.2020.01.027. Epub 2020 Mar 10.
8
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications.MET在非小细胞肺癌对表皮生长因子受体抑制的耐药中的作用：机制及治疗意义综述
Cancers (Basel). 2023 May 31;15(11):2998. doi: 10.3390/cancers15112998.
9
Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.免疫疗法在致癌基因驱动的非小细胞肺癌患者中的疗效：一项系统评价和荟萃分析。
Ther Adv Med Oncol. 2024 Feb 27;16:17588359231225036. doi: 10.1177/17588359231225036. eCollection 2024.
10
Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.Krüppel 样因子 4 促进非小细胞肺癌中 c-Met 扩增介导的吉非替尼耐药。
Cancer Sci. 2018 Jun;109(6):1775-1786. doi: 10.1111/cas.13601. Epub 2018 May 21.

引用本文的文献

1
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer.免疫疗法的新前沿：嵌合抗原受体T（CAR-T）细胞和巨噬细胞（CAR-M）治疗乳腺癌
Cancers (Basel). 2023 Mar 4;15(5):1597. doi: 10.3390/cancers15051597.
2
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells and .靶向c-Met的嵌合抗原受体T细胞抑制肝癌细胞 以及 。 （原文句末不完整，翻译可能存在一定局限性）
J Biomed Res. 2021 Dec 16;36(1):10-21. doi: 10.7555/JBR.35.20200207.
3
Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis.MET拷贝数增加在非小细胞肺癌中的预后价值：一项更新的荟萃分析。
J Cancer. 2018 Apr 23;9(10):1836-1845. doi: 10.7150/jca.24980. eCollection 2018.
4
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.嵌合抗原受体（CAR）T 细胞瘤内注射治疗转移性乳腺癌的安全性和疗效。
Cancer Immunol Res. 2017 Dec;5(12):1152-1161. doi: 10.1158/2326-6066.CIR-17-0189. Epub 2017 Nov 6.
5
MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review.晚期非小细胞肺癌中的MET抑制剂：一项荟萃分析与综述
Oncotarget. 2017 Sep 11;8(43):75500-75508. doi: 10.18632/oncotarget.20824. eCollection 2017 Sep 26.
6
MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.MET 激活与转移过程的物理动力学：以不明原发灶癌为例。
EBioMedicine. 2017 Oct;24:34-42. doi: 10.1016/j.ebiom.2017.09.025. Epub 2017 Sep 21.
7
Predicting ligand-dependent tumors from multi-dimensional signaling features.从多维信号特征预测配体依赖性肿瘤。
NPJ Syst Biol Appl. 2017 Sep 20;3:27. doi: 10.1038/s41540-017-0030-3. eCollection 2017.
8
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.氟尿嘧啶、亚叶酸和奥沙利铂联合或不联合奥妥珠单抗治疗人表皮生长因子受体 2（HER2）阴性、间质上皮转化因子（MET）阳性胃食管腺癌的效果：METGastric 随机临床试验。
JAMA Oncol. 2017 May 1;3(5):620-627. doi: 10.1001/jamaoncol.2016.5580.
9
MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.透明细胞肾细胞癌中MET的表达及拷贝数状态：预后价值及潜在预测标志物
Oncotarget. 2017 Jan 3;8(1):1046-1057. doi: 10.18632/oncotarget.13540.
10
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.血清肝细胞生长因子水平降低与阿法替尼治疗晚期肺腺癌患者预后改善相关：一项 II 期试验。
Target Oncol. 2016 Oct;11(5):619-629. doi: 10.1007/s11523-016-0425-x.

本文引用的文献

1
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.三期多国、随机、双盲、安慰剂对照研究：替沃扎尼（ARQ 197）联合厄洛替尼对比厄洛替尼单药治疗既往治疗的局部晚期或转移性非鳞状非小细胞肺癌患者。
J Clin Oncol. 2015 Aug 20;33(24):2667-74. doi: 10.1200/JCO.2014.60.7317. Epub 2015 Jul 13.
2
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.随机 II 期试验：奥沙利umab 联合厄洛替尼治疗晚期非小细胞肺癌患者。
J Clin Oncol. 2013 Nov 10;31(32):4105-14. doi: 10.1200/JCO.2012.47.4189. Epub 2013 Oct 7.
3
Targeting MET in cancer: rationale and progress.靶向 MET 治疗癌症：原理与进展。
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205.
4
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.MET增加了非小细胞肺癌患者的基因拷贝数以及对吉非替尼治疗的原发性耐药性。
Ann Oncol. 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. Epub 2008 Oct 3.